Results 201 to 210 of about 6,006,467 (356)

C3 glomerulopathy: a kidney disease mediated by alternative pathway deregulation. [PDF]

open access: yesFront Nephrol
Heidenreich K   +8 more
europepmc   +1 more source

Correction: A potent complement factor C3-specific nanobody inhibiting multiple functions in the alternative pathway of human and murine complement. [PDF]

open access: yesJ Biol Chem, 2023
Jensen RK   +7 more
europepmc   +1 more source

Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockade

open access: yesMolecular Oncology, EarlyView.
Rolig, Peng, and colleagues have shed new light on how dual blockade of PD1 and LAG3 enhances antitumor immunity. They found that response to immunotherapy with anti‐PD1 + anti‐LAG3 was associated with reprogramming of canonically suppressive CD4+ regulatory T cells to an inflammatory state.
Tullia C. Bruno, Anthony R. Cillo
wiley   +1 more source

Differential effects of C5 inhibition, C3 inhibition, and alternative pathway inhibition on bacterial killing in vitro. [PDF]

open access: yesBlood Adv
Ter Avest M   +6 more
europepmc   +1 more source

Arginine Decarboxylase and Agmatinase: An Alternative Pathway for De Novo Biosynthesis of Polyamines for Development of Mammalian Conceptuses1

open access: yesBiology of Reproduction, 2014
Xiaoqiu Wang   +7 more
semanticscholar   +1 more source

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

open access: yesMolecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy